Type 1 diabetes incidence has increased dramatically over the last 20 years, especially in children less than 5 years of age. We can now predict who will develop diabetes but not yet prevent the disease. Many therapies have been used to target the immune system and the white blood cells involved in killing insulin-producing cells in an attempt to treat and prevent type 1 diabetes. We know that regulatory T cells within the immune system can dampen and prevent the damage caused by destructive cells involved in autoimmunity. Through my research, I am characterizing the regulatory T cells in order to develop a safe and specific therapy to stop the immune destruction of insulin-producing cells in type 1 diabetes patients.